In the latest close session, Amgen (AMGN) was down 1.73% at $301.29. The stock's change was less than the S&P 500's daily gain of 0.02%. Meanwhile, the Dow experienced a drop of 0.14%, and the technology-dominated Nasdaq saw an increase of 0.33%.
The world's largest biotech drugmaker's shares have seen an increase of 10.63% over the last month, surpassing the Medical sector's gain of 1.92% and the S&P 500's gain of 4.93%.
Investors will be eagerly watching for the performance of Amgen in its upcoming earnings disclosure. The company's earnings report is set to be unveiled on August 5, 2025. The company's upcoming EPS is projected at $5.25, signifying a 5.63% increase compared to the same quarter of the previous year. Our most recent consensus estimate is calling for quarterly revenue of $8.86 billion, up 5.64% from the year-ago period.
AMGN's full-year Zacks Consensus Estimates are calling for earnings of $20.87 per share and revenue of $35.23 billion. These results would represent year-over-year changes of +5.19% and +5.41%, respectively.
Investors should also take note of any recent adjustments to analyst estimates for Amgen. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been a 0.24% rise in the Zacks Consensus EPS estimate. Amgen is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that Amgen has a Forward P/E ratio of 14.69 right now. This represents a discount compared to its industry average Forward P/E of 20.33.
We can also see that AMGN currently has a PEG ratio of 2.65. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.75 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. With its current Zacks Industry Rank of 89, this industry ranks in the top 37% of all industries, numbering over 250.
The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Amgen Inc. (AMGN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
